The medical device space is growing rapidly as new startups and investments from major players enter the market. Some of the most notable investors in medical devices include venture capital firms such as Kleiner Perkins Caufield & Byers, Sequoia Capital, and Accel Partners, as well as large companies such as Johnson & Johnson and Medtronic.
This influx of investment is driving innovation in the medical device space, with new devices and treatments being developed all the time. This growth is also creating opportunities for entrepreneurs, who can now launch their own medical device startups and access funding from major players.
Good Laboratory Practice certification expands company’s ability to support medical device manufacturers in meeting the complex demands of international regulatory frameworks.
Robert Krummen, CEO of Vektor Medical. “With every procedure, physicians are leveraging vMap’s rapid, non-invasive insights to make informed decisions and streamline care. We’re seeing growing demand quarter over quarter as both physicians and hospitals look for ways to enhance efficiency and elevate patient care.”
Alzheimer’s disease affects more than 6 million Americans, and emerging research identifies Obstructive Sleep Apnea (OSA) as a significant, modifiable risk factor. Interrupted breathing during sleep can impair memory and accelerate cognitive decline, with growing evidence linking poor sleep to an increased risk of dementia. In response, Vivos Therapeutics is offering innovative, airway-centered treatments aimed at improving sleep quality and supporting long-term brain health.
Guy Spörri, CEO of Movora said, “This agreement represents a significant step forward in our mission to support veterinary professionals with world-class surgical technologies.”
This agreement includes the first 400 cm, 0.018″ peripheral guidewire available in the U.S, expanding the Medtronic portfolio for transradial access for the treatment of peripheral arterial disease (PAD).
“We are encouraged by CMS’s proposed decision to provide Medicare coverage for uRDN in patients with uncontrolled hypertension—a population that continues to face significant unmet need,” said Lara Barghout, CEO of Recor Medical.